Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Slovenia: These 39 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "Slovenia: These 39 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

When can TYMLOS (abaloparatide) generic drug versions launch in Slovenia?

Generic name: abaloparatide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Slovenia Patent 2,957,278

TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in Slovenia?

Generic name: cobimetinib fumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Slovenia Patent 1,934,174

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch in Slovenia?

Generic name: sacubitril; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Slovenia Patent 2,340,828

ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. Additional details are available on the sacubitril; valsartan profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Slovenia?

Generic name: piflufolastat f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Slovenia Patent 2,097,111

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Slovenia?

Generic name: piflufolastat f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Slovenia Patent 2,097,111

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch in Slovenia?

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Slovenia Patent 2,064,228

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.

When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Slovenia?

Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Slovenia Patent 2,101,740

ZUBSOLV is a drug marketed by Edenbridge Pharms. There are ten patents protecting this drug and four Paragraph IV challenges. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering ZUBSOLV

See drug price trends for ZUBSOLV.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Slovenia?

Generic name: bedaquiline fumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Slovenia Patent 2,086,940

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Slovenia?

Generic name: ceritinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Slovenia Patent 2,091,918

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Slovenia?

Generic name: ingenol mebutate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Slovenia Patent 1,988,877

PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Slovenia?

Generic name: sarecycline hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Slovenia Patent 2,120,963

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: ponatinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Slovenia Patent 1,973,545

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: ponatinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Slovenia Patent 2,495,016

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Slovenia?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Slovenia Patent 2,107,905

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Slovenia?

Generic name: lefamulin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Slovenia Patent 2,137,143

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can INLYTA (axitinib) generic drug versions launch in Slovenia?

Generic name: axitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Slovenia Patent 2,134,702

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Slovenia Patent 2,007,756

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Slovenia Patent 2,674,428

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Slovenia Patent 3,091,011

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Slovenia Patent 3,327,016

When can TRADJENTA (linagliptin) generic drug versions launch in Slovenia?

Generic name: linagliptin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: Slovenia Patent 2,283,819

TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Slovenia?

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,152,237

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Slovenia?

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Slovenia Patent 3,090,730

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Slovenia?

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Slovenia Patent 4,218,732

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Slovenia?

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Slovenia Patent 4,400,104

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Slovenia?

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Slovenia Patent 2,164,467

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Slovenia?

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Slovenia Patent 2,500,014

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Slovenia?

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Slovenia Patent 2,164,467

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Slovenia?

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Slovenia Patent 2,500,014

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Slovenia?

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Slovenia Patent 2,740,731

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Slovenia?

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Slovenia Patent 3,070,090

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in Slovenia?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Slovenia Patent 2,719,378

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Slovenia?

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Slovenia Patent 2,069,374

BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Slovenia?

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Slovenia Patent 2,069,374

FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fourteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Slovenia?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Slovenia Patent 2,069,374

QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Slovenia?

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Slovenia Patent 2,081,921

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Slovenia?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,450,035

EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Slovenia?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,450,035

EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,164,843

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,164,844

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,754,660

When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch in Slovenia?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Slovenia Patent 2,016,940

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can TRIFERIC AVNU (ferric pyrophosphate citrate) generic drug versions launch in Slovenia?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Slovenia Patent 2,016,940

TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.

See drug price trends for TRIFERIC AVNU.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can MULPLETA (lusutrombopag) generic drug versions launch in Slovenia?

Generic name: lusutrombopag
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 31, 2027
Generic Entry Controlled by: Slovenia Patent 2,184,279

MULPLETA is a drug marketed by Vancocin Italia. There are three patents protecting this drug.

See drug price trends for MULPLETA.

The generic ingredient in MULPLETA is lusutrombopag. Additional details are available on the lusutrombopag profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Slovenia?

Generic name: clascoterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,173,891

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Slovenia?

Generic name: clascoterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,503,004

When can WINLEVI (clascoterone) generic drug versions launch in Slovenia?

Generic name: clascoterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,503,005

When can WINLEVI (clascoterone) generic drug versions launch in Slovenia?

Generic name: clascoterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,966,175

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Slovenia?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Slovenia Patent 2,187,965

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Slovenia?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,207,526

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can MYRBETRIQ (mirabegron) generic drug versions launch in Slovenia?

Generic name: mirabegron
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2027
Generic Entry Controlled by: Slovenia Patent 2,216,021

MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering MYRBETRIQ

See drug price trends for MYRBETRIQ.

The generic ingredient in MYRBETRIQ is mirabegron. Additional details are available on the mirabegron profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Slovenia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Slovenia Patent 2,222,285

VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Slovenia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Slovenia Patent 3,143,992

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Slovenia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Slovenia Patent 3,895,699

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Slovenia?

Generic name: allopurinol; lesinurad
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Slovenia Patent 2,217,577

DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Slovenia?

Generic name: lesinurad
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Slovenia Patent 2,217,577

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

Last updated: May 12, 2026

Slovenia Branded vs Generic Drug Markets Assessment, Regulatory Pathways, and IP/Entry Challenges

Slovenia is a small EU member state with a tightly controlled medicines environment: mandatory reference pricing and reimbursement governance drive usage toward lower-cost alternatives, while parallel imports and prescribing practices shape launch timing and realized pricing. For branded manufacturers, the market risk is rapid erosion from generics where patent and data exclusivity have lapsed and where reimbursement incentives favor substitutes. For generic and biosimilar entrants, the primary execution risk is not demand but regulatory and legal lead time: dossier readiness for EU variation procedures, transparency around manufacturing and quality, and the ability to clear national pricing/reimbursement thresholds quickly after launch.

The practical opportunity set is strongest for (1) follow-on products with clear regulatory pathways (generic, hybrid, line-extension) and (2) products that can price into Slovenia’s reimbursement framework without triggering reimbursement delays or constrained formularies. The main challenge set is (a) price compression under reference pricing and external reference models, (b) limited reimbursement budget headroom that amplifies payer scrutiny, and (c) litigation or IP barriers that can delay “effective” market entry even after EMA authorization.

How big is the Slovenia branded drug market versus generics, and what drives volume?

Answer: Slovenia’s outpatient consumption has a structurally high generics share by volume in many ATC classes, driven by reimbursement policy, reference pricing, and prescriber incentives, while branded products retain hold where there is clinical differentiation, limited substitution, or payer-managed positioning.

Key demand dynamics

EU authorization does not equal market uptake. EMA marketing authorization is necessary but not sufficient; reimbursement decisions determine pharmacy uptake.
Reference pricing compresses branded prices. When generics enter, brand pricing typically falls toward the reference level to retain reimbursement access.
Substitution rules and reimbursement design influence pharmacy substitution. When payers reimburse only up to a ceiling, generics gain share quickly even with modest patient switching friction.
Budget cycles accelerate market responses. Slovenia’s reimbursement negotiations and periodic updates can shift preferred reimbursement status within quarters rather than years.

What to expect by product type

Branded originators (still within exclusivity or with payer preference): Higher persistence, but price risk if reference pricing triggers.
Generics: Often capture most incremental volume once eligibility and reimbursement ceilings are reached, subject to packaging, availability, and any substitution constraints.
Biosimilars: Uptake depends on therapeutic area, prescriber patterns, and tendering or hospital formulary decisions. Tender design can override list-price differences.

How does Slovenia regulate medicines pricing and reimbursement for branded versus generic drugs?

Answer: Pricing and reimbursement are governed under an EU-aligned national framework with reference pricing and payer budget oversight. Generic penetration is supported by pricing mechanisms that make reimbursed pricing converge quickly toward the lowest-cost comparable products.

Mechanisms that typically favor generics

Reference pricing: Creates a reimbursement ceiling linked to comparable alternatives, reducing brand ability to sustain higher reimbursement-linked prices after generic entry.
Reimbursement listing and formulary management: Products need favorable listing status to achieve broad payer-driven use.
Budget impact review: Payers prioritize cost-effectiveness, which frequently strengthens the value proposition of low-cost generics.

Mechanisms that can protect brands

Clinical differentiation and evidence breadth: If payers accept differentiated outcomes, brands can retain higher reimbursement positioning longer in selected categories.
Exclusivity windows: Regulatory and marketing exclusivity can delay generic substitution and preserve higher reimbursement rates until lapsing.

What is the Orange Book equivalent in Slovenia for drug patents and exclusivity, and how is IP enforced?

Answer: Slovenia does not use the US Orange Book construct, but IP and data protection are enforced through national and EU patent systems, and exclusivity protections affect generic eligibility through regulatory approval gating.

Where IP barriers show up in practice

Regulatory eligibility timing: Even if a generic can prepare a dossier, market entry can be blocked by exclusivity, patent rights, or litigation outcomes.
Court outcomes drive “effective launch.” Settlement terms, injunctions, and stay effects can dictate if a product is sold at launch date or later.

Operational implication

For branded holders: track cross-border patent filings that can trigger actions affecting EU authorization holders.
For generic entrants: plan for litigation risk that can compress launch windows and increase cost of goods under delayed sales start.

When do branded drugs lose exclusivity in Slovenia, and how does it affect generic launch timing?

Answer: Generic entry timing is driven by a combination of regulatory data/marketing exclusivity and patent status, with the practical inflection point occurring when both regulatory barriers and actionable IP constraints are cleared.

Timing model for entry

Regulatory exclusivity end: Data/marketing exclusivity expiration determines when the generic can receive approval on the basis of originator data.
Patent expiry or clearance: Patent expiry or successful challenge/litigation clearance determines when commercialization is permitted.
Reimbursement listing and price negotiation: Even after approval, payer listing and reference pricing rules determine how quickly volume ramps.

Launch risk mapping

Approval-only success is not market success. A product can be approved but still face a delayed reimbursement listing or unfavorable reference pricing bucket that slows uptake.
Brand discounting may be strategic. Originators can cut prices after competitor entry to preserve reimbursement position, affecting realized pricing for entrants.

Which regulatory pathway does Slovenia use for generics and what filings matter for market entry?

Answer: Slovenia follows EU medicines law. Generic approvals and variations are processed through EU frameworks after EMA authorization, with national steps then affecting reimbursement listing and commercial uptake.

Regulatory pathway checklist for generic entry

EMA generic authorization: Must comply with EU generic standards: demonstration of bioequivalence or requirement-based waivers, quality documentation, and labeling alignment.
Quality and manufacturing oversight: GMP compliance and validated processes are a principal gating factor for launch readiness.
Variations strategy: Post-approval manufacturing changes must be managed through EU variation categories without triggering additional delays that affect market supply.

Common execution failure points

Packaging and labeling alignment: Country-specific package leaflet and labeling must be consistent with Slovenian requirements.
Supply chain validation: Short lead times between reimbursement listing and pharmacy distribution can expose logistics gaps.

What biosimilar opportunities exist in Slovenia, and how do interchangeability and tendering affect uptake?

Answer: Biosimilar opportunity in Slovenia is real but operationally sensitive. Uptake is strongly influenced by hospital procurement and formulary decisions rather than only pharmacy-level substitution.

Biosimilar uptake drivers

Tender procurement rules: Competitive pricing can determine the winning product in hospital-led therapeutic use.
Hospital formularies and treatment pathways: These decide switching rates and continuity of prescribing.
Clinical governance and safety switching protocols: Even where biosimilars are authorized, internal switching frameworks slow adoption in some indications.

Strategic implication

Plan commercialization with a dual-track approach:
- regulatory readiness for EU authorization,
- payer and provider engagement for hospital formulary inclusion and tender participation.

What formulations and delivery systems are most likely to see generic competition in Slovenia?

Answer: Lower complexity oral solid formulations and established dosage forms typically face the fastest generic competition. Complex delivery systems face higher development costs and longer regulatory and technical barriers.

Higher-probability generic areas

Oral tablets and capsules with mature APIs
Simple topical products with stable quality attributes and accessible reference standards
Solutions and suspensions where formulation equivalence is straightforward

Higher-barrier areas

Modified release
Narrow therapeutic index products
Complex inhalation or injectables where bioequivalence is more complex and batch-to-batch variability is scrutinized

How do pricing controls and reference categories affect generic profit margins in Slovenia?

Answer: Reference pricing and reimbursement ceilings typically compress margins, making scale, supply efficiency, and rapid uptake critical for positive unit economics.

Margin squeeze dynamics

Price convergence after entry: Once a generic is eligible for reimbursement within a reference cluster, the reimbursed price ceiling tends to pull all comparable products toward the lowest-cost option.
Reimbursement-driven switching: If prescribers and pharmacists respond to ceilings, volume shifts quickly, leaving less time for price skimming.
External reference pricing effects: EU alignment means price levels can be influenced by broader market comparisons.

Commercial execution priorities

Optimize manufacturing cost structure for Slovenia scale.
Ensure availability to avoid losing early share during high-intent period post-listing.
Build a coverage strategy across pack sizes to maximize fit with patient and dosing needs.

What patent litigation risks exist for generic entry in Slovenia’s EU setting?

Answer: Patent litigation risk in Slovenia tracks broader EU enforcement realities: litigation over patents and exclusivity can delay commercialization even when regulatory authorization is feasible.

Where disputes arise

Primary patents: Composition-of-matter and polymorph claims
Secondary patents: Manufacturing method, process improvements, and specific formulation claims
Use patents: Method-of-use claims that can restrict labeling or indications

Settlement and launch sequencing

Settlements can coordinate entry timelines with delayed sales dates or limited launches (for example, specific strengths or pack types).
Injunctions can halt sales even after EMA approval.

How strong is the patent estate that typically protects branded products relevant to Slovenia’s reimbursement decisions?

Answer: Patent estates that span multiple mechanisms (composition, formulations, manufacturing, and uses) are common, and they can extend effective exclusivity beyond nominal regulatory timelines for specific strengths, indications, or formulations.

Common portfolio patterns

“Evergreening” formulations: New polymorphs, salts, or formulation improvements that can be covered by new patents
Device or delivery system patents: For inhalation or injectable delivery systems
Process patents: Manufacturing route improvements that complicate generic replication

Implication for challengers

Dossier readiness must incorporate freedom-to-operate checks by strength and formulation, not only by active ingredient.
Launch planning should align with expected litigation outcomes and the reimbursement listing calendar.

Which companies are likely active in Slovenia for branded and generic medicines and what are the competitive patterns?

Answer: Slovenia’s competitive pattern follows EU trends: international originator brands with local distributor networks, and EU generic manufacturers with EMA-authorized products that pursue Slovenia reimbursement listing for volume capture.

Competition pattern by market channel

Outpatient pharmacy channel: Highly sensitive to reimbursement ceilings and substitution behaviors.
Hospital channel: Driven by tender cycles and formulary inclusion for products with hospital-led therapy pathways.

Competitive action points

Brands: defend reimbursement position through pricing strategy and payer evidence.
Generics: prioritize speed to reimbursement listing and uninterrupted supply.

What are the regulatory opportunities for entrants in Slovenia: reformulation, line extensions, and new strengths?

Answer: Line extensions and reformulations can create exploitable regulatory opportunities, but only when they satisfy EU authorization requirements and do not infringe active IP.

High-fit opportunity categories

Generic “hybrid” products where bioequivalence can be demonstrated with feasible studies.
Line extensions where patent coverage is weaker or has already lapsed for specific strengths.
Device or administration improvements if they have a defensible regulatory and IP position.

Risk controls

Conduct strength-by-strength IP screening.
Align regulatory development timelines with expected reimbursement listing windows.

What are the biggest barriers to market entry for generic companies in Slovenia?

Answer: The bottlenecks are mostly commercial-regulatory. Regulatory approval is typically achievable within EMA frameworks, but reimbursement listing timing and reference pricing determine realized uptake and profitability.

Top barriers in practice

Reimbursement delays: Administrative cycles and budget review can slow net sales ramp.
Reference pricing: Forces rapid price declines, shrinking margin.
IP enforcement and litigation: Can limit sales even after EMA authorization.
Supply continuity: Small-market scale makes stockouts unusually damaging to early share capture.

Slovenia regulatory timeline for generic launch: what steps happen after EMA authorization?

Answer: After EMA authorization, the entry pathway shifts from regulatory science to commercial access: reimbursement listing, price negotiation under reference frameworks, labeling readiness, and distribution setup.

Typical sequencing

EMA authorization complete
Prepare Slovenia labeling and product registration for commercialization
Submit reimbursement-related documentation
Price determination under reference pricing rules
Pharmacy distribution and contracting
Managed substitution and uptake acceleration after listing

Time-to-market risk levers

Availability of documentation and translation readiness.
How quickly the product is slotted into the appropriate reimbursement cluster.
Any ongoing IP disputes affecting “effective” launch.

Key Takeaways

Slovenia’s branded-to-generic shift is driven mainly by reimbursement mechanics, not EMA authorization alone.
Reference pricing compresses brand pricing power after generic entry and reduces generic differentiation opportunities.
Regulatory pathways for generics are EU-led; the bottleneck for commercial impact is reimbursement listing timing and reference-category alignment.
IP risk affects launch effectiveness through litigation and exclusivity gating, requiring strength- and formulation-level freedom-to-operate planning.
Biosimilars face hospital-driven adoption constraints tied to tenders and formularies, making provider engagement as important as dossier strategy.

FAQs

How do Slovenia reimbursement ceilings affect pharmacy switching between branded and generic drugs?
What data requirements most commonly delay generic approvals for oral solid products in Slovenia’s EU framework?
When does patent litigation most often delay generic commercialization after an EMA approval?
How do hospital tenders influence biosimilar uptake in Slovenia compared with outpatient substitution?
What operational steps most reduce time-to-reimbursement listing for generics in Slovenia after EMA authorization?

References

No sources were cited in the provided content.

Slovenia Branded vs Generic Drug Markets Assessment, Regulatory Pathways, and IP/Entry Challenges

How big is the Slovenia branded drug market versus generics, and what drives volume?

Key demand dynamics

What to expect by product type

How does Slovenia regulate medicines pricing and reimbursement for branded versus generic drugs?

Mechanisms that typically favor generics

Mechanisms that can protect brands

What is the Orange Book equivalent in Slovenia for drug patents and exclusivity, and how is IP enforced?

Where IP barriers show up in practice

Operational implication

When do branded drugs lose exclusivity in Slovenia, and how does it affect generic launch timing?

Timing model for entry

Launch risk mapping

Which regulatory pathway does Slovenia use for generics and what filings matter for market entry?

Regulatory pathway checklist for generic entry

Common execution failure points

What biosimilar opportunities exist in Slovenia, and how do interchangeability and tendering affect uptake?

Biosimilar uptake drivers

Strategic implication

What formulations and delivery systems are most likely to see generic competition in Slovenia?

Higher-probability generic areas

Higher-barrier areas

How do pricing controls and reference categories affect generic profit margins in Slovenia?

Margin squeeze dynamics

Commercial execution priorities

What patent litigation risks exist for generic entry in Slovenia’s EU setting?

Where disputes arise

Settlement and launch sequencing

How strong is the patent estate that typically protects branded products relevant to Slovenia’s reimbursement decisions?

Common portfolio patterns

Implication for challengers

Which companies are likely active in Slovenia for branded and generic medicines and what are the competitive patterns?

Competition pattern by market channel

Competitive action points

What are the regulatory opportunities for entrants in Slovenia: reformulation, line extensions, and new strengths?

High-fit opportunity categories

Risk controls

What are the biggest barriers to market entry for generic companies in Slovenia?

Top barriers in practice

Slovenia regulatory timeline for generic launch: what steps happen after EMA authorization?

Typical sequencing

Time-to-market risk levers

Key Takeaways

FAQs

References

Make Better Decisions: Try a trial or see plans & pricing